drugset / Trial / NCT03925935
Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
Phase 1
Completed
42 enrolled
Angiocrine Bioscience
California Institute for Regenerative Medicine (CIRM) · collab
NaSequentialOpen-labelTreatment
Summary
A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without radiation, and autologous stem cell transplantation (HDT-ASCT). Subjects will receive AB-205 infusion following autologous stem cell transfusion on Day 0.
Timeline
- Start
- 2019-05-07
- Primary completion
- 2020-11-18
- Completion
- 2021-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AB-205 | Cell therapy | — | — |